CYP19A1 and breast cancer: In this single-center, cross-sectional study, 556 postmenopausal women with early-stage breast cancer were consecutively enrolled from October 15, 2013, to June 30, 2018, and stratified according to whether they were aromatase inhibitor–naive or aromatase inhibitor–treated for at least 2 years.